Global Markets Direct’s, 'Joint Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Joint Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Joint Pain. Joint Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Joint Pain. - A review of the Joint Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Joint Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Joint Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Joint Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Joint Pain - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Joint Pain Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Joint Pain 6 Joint Pain Therapeutics under Development by Companies 8 Late Stage Products 9 Comparative Analysis 9 Early Clinical Stage Products 10 Comparative Analysis 10 Joint Pain Therapeutics - Products under Development by Companies 11 Companies Involved in Joint Pain Therapeutics Development 12 Viromed Co., Ltd. 12 Joint Pain - Therapeutics Assessment 13 Assessment by Monotherapy Products 13 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Drug Profiles 18 PG-201 - Drug Profile 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 leconotide - Drug Profile 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 Joint Pain Therapeutics - Discontinued Products 20 Joint Pain Therapeutics - Dormant Products 21 Joint Pain - Product Development Milestones 22 Featured News and Press Releases 22 Sep 19, 2012: Imprimis Pharma To Begin New Study Of Topical Analgesic Drug 22 Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial With TG-C 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 25 Disclaimer 25
List of Tables
Number of Products Under Development for Joint Pain, H1 2013 6 Products under Development for Joint Pain - Comparative Analysis, H1 2013 7 Number of Products under Development by Companies, H1 2013 8 Comparative Analysis by Late Stage Development, H1 2013 9 Comparative Analysis by Early Clinical Stage Development, H1 2013 10 Products under Development by Companies, H1 2013 11 Viromed Co., Ltd., H1 2013 12 Assessment by Monotherapy Products, H1 2013 13 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Stage and Molecule Type, H1 2013 17 Joint Pain Therapeutics - Discontinued Products 20 Joint Pain Therapeutics - Dormant Products 21
List of Figures
Number of Products under Development for Joint Pain, H1 2013 6 Products under Development for Joint Pain - Comparative Analysis, H1 2013 7 Products under Development by Companies, H1 2013 8 Late Stage Products, H1 2013 9 Early Clinical Stage Products, H1 2013 10 Assessment by Monotherapy Products, H1 2013 13 Assessment by Route of Administration, H1 2013 14 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Molecule Type, H1 2013 16 Assessment by Stage and Molecule Type, H1 2013 17